Section Arrow
Quote
BLSM.NASDAQ
- BlossomHill Therapeutics, Inc.
Quotes are at least 15-min delayed:2026/09/22 05:15 EDT
Pre Market
Last
 --
-- (--)
Bid
16
Ask
40
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 26.8
+1.06 (+4.12%)
Day High 
27.99 
Prev. Close
25.74 
1-M High
27.8 
Volume 
292.22K 
Bid
16
Ask
40
Day Low
25.115 
Open
26.09 
1-M Low
15.6 
Market Cap 
748.55M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 23.2 
20-SMA 20.87 
50-SMA -- 
52-W High 27.8 
52-W Low 15.25 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.66/-2.99
Enterprise Value
770.94M
Balance Sheet
Book Value Per Share
-5.50
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
RXRXRecursion Pharmaceuticals3.97+0.14+3.66%-- 
Pre Market 3.93 -0.04 -1.01%
MRNAModerna172.94+18.9+12.27%-- 
Pre Market 170.12 -2.82 -1.63%
SLXNSilexion Therapeutics Corp.0.5441+0.1086+24.94%-- 
Pre Market 0.67 +0.1259 +23.14%
CELZCreative Medical Technology Holdings1.005+0.0391+4.05%-- 
Pre Market 0.885 -0.12 -11.94%
PDSBPDS Biotechnology Corp0.8419+0.0364+4.52%-- 
Pre Market 0.831 -0.0109 -1.29%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.